Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 36

Results For "diabetes"

553 News Found

Eris Lifesciences buys India formulation business of Biocon Biologics for Rs. 1,242 Cr
News | March 17, 2024

Eris Lifesciences buys India formulation business of Biocon Biologics for Rs. 1,242 Cr

Both organisations enter into a long- term collaboration to expand patient access in India


Briefs: IOL Chemicals and Pharmaceuticals and Auro Peptides
News | February 20, 2024

Briefs: IOL Chemicals and Pharmaceuticals and Auro Peptides

IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China


100 bedded Yoga & Naturopathy Hospital to come up in Dibrugarh
News | January 30, 2024

100 bedded Yoga & Naturopathy Hospital to come up in Dibrugarh

Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy


Bayer, Sun Pharma sign marketing and distribution agreement for second brand of Finerenone in India
News | January 17, 2024

Bayer, Sun Pharma sign marketing and distribution agreement for second brand of Finerenone in India

Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa


Lupin receives tentative approval from USFDA for Dapagliflozin and Saxagliptin tablets
Drug Approval | January 04, 2024

Lupin receives tentative approval from USFDA for Dapagliflozin and Saxagliptin tablets

Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US


Glenmark to launch biosimilar of anti-diabetic drug Liraglutide in India
News | January 03, 2024

Glenmark to launch biosimilar of anti-diabetic drug Liraglutide in India

Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs


Lupin receives tentative USFDA approval for Sitagliptin Tablets
Drug Approval | December 18, 2023

Lupin receives tentative USFDA approval for Sitagliptin Tablets

Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus


Zepbound is now available in US for adults living with obesity
News | December 09, 2023

Zepbound is now available in US for adults living with obesity

Express Scripts to add Zepbound to National Preferred Formulary


Indoco Remedies receives tentative ANDA approval from USFDA for Canagliflozin Tablets
Drug Approval | December 07, 2023

Indoco Remedies receives tentative ANDA approval from USFDA for Canagliflozin Tablets

This product will be manufactured by Indoco Remedies at their manufacturing facility located at Goa